News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
832,464 Results
Type
Article (85652)
Company Profile (746)
Press Release (746066)
Section
Business (232274)
Career Advice (4107)
Deals (39648)
Drug Delivery (118)
Drug Development (90677)
Employer Resources (194)
FDA (17983)
Job Trends (17274)
News (395627)
Policy (39625)
Tag
Academia (2975)
Alliances (56490)
Alzheimer's disease (1347)
Approvals (17890)
Artificial intelligence (171)
Bankruptcy (394)
Best Places to Work (12537)
Biotechnology (510)
Breast cancer (147)
Cancer (1241)
Cardiovascular disease (116)
Career advice (3513)
Cell therapy (278)
Clinical research (71653)
Collaboration (444)
Compensation (219)
COVID-19 (2806)
C-suite (114)
Data (1212)
Diabetes (173)
Diagnostics (6700)
Drug pricing (103)
Earnings (94779)
Employer resources (167)
Events (127064)
Executive appointments (345)
FDA (18584)
Funding (400)
Gene therapy (208)
GLP-1 (701)
Government (5050)
Healthcare (20733)
Infectious disease (2901)
Inflammatory bowel disease (123)
Interviews (807)
IPO (17606)
Job creations (5179)
Job search strategy (2855)
Layoffs (491)
Legal (10045)
Lung cancer (194)
Manufacturing (207)
Medical device (14428)
Medtech (14433)
Mergers & acquisitions (22114)
Metabolic disorders (481)
Neuroscience (1667)
NextGen Class of 2024 (7657)
Non-profit (5065)
Northern California (1581)
Obesity (273)
Opinion (244)
Patents (118)
People (64235)
Pharmaceutical (149)
Phase I (22057)
Phase II (31113)
Phase III (23458)
Pipeline (487)
Postmarket research (3541)
Preclinical (9971)
Radiopharmaceuticals (259)
Rare diseases (257)
Real estate (7373)
Regulatory (26006)
Research institute (2642)
Resumes & cover letters (648)
Southern California (1381)
Startups (4276)
United States (15141)
Vaccines (657)
Weight loss (222)
Date
Today (118)
Last 7 days (409)
Last 30 days (3524)
Last 365 days (38425)
2024 (36132)
2023 (42566)
2022 (53928)
2021 (58726)
2020 (57671)
2019 (51341)
2018 (39125)
2017 (37191)
2016 (38330)
2015 (44433)
2014 (39673)
2013 (36268)
2012 (38416)
2011 (38383)
2010 (39616)
Location
Africa (1265)
Arizona (229)
Asia (49400)
Australia (8703)
California (3668)
Canada (1358)
China (285)
Colorado (163)
Connecticut (182)
Europe (113124)
Florida (496)
Georgia (133)
Illinois (431)
Indiana (224)
Maryland (651)
Massachusetts (2973)
Michigan (181)
Minnesota (303)
New Jersey (1048)
New York (1041)
North Carolina (858)
Northern California (1581)
Ohio (152)
Pennsylvania (895)
South America (1647)
Southern California (1381)
Texas (543)
Washington State (413)
There are 832,464 results that match your search.
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Layoff Tracker
Alligator Bioscience Cuts 70% of Staff Amid ‘Capital Constraints’
Follow along as
BioSpace
keeps you up-to-date on the latest pharma and biotech layoffs.
December 3, 2024
·
196 min read
·
BioSpace Editorial Staff
Neuroscience
Intra-Cellular Eyes Depression Approval for Caplyta as Stock Flies Under the Radar
Intra-Cellular submitted its application to the FDA for Caplyta’s approval in major depressive disorder, potentially opening up an additional $1 billion in sales. Still, the stock remains “cheap,” according to Jefferies analysts.
December 3, 2024
·
4 min read
·
Annalee Armstrong
Collaboration
Takeda Puts Up to $1.3B on the Line for Keros’ Blood Cancer Anemia Drug
Keros’ elritercept has shown promising efficacy signals in myelofibrosis and myelodysplastic syndromes and could pose a formidable challenge to Bristol Myers Squibb’s Reblozyl.
December 3, 2024
·
2 min read
·
Tristan Manalac
Immunology & inflammation
Roche Partners With COUR in Autoimmune Deal Potentially Worth More Than $900M
The collaboration will see COUR and Roche’s Genentech leverage the biotech’s antigen-specific immune tolerance platform to develop and commercialize therapies for an undisclosed autoimmune disease.
December 3, 2024
·
1 min read
·
Heather McKenzie
Antibody-drug conjugate
Gilead Plots ADC Comeback With Potential $415M License Agreement
The deal with Tubulis will help Gilead regain its footing in the ADC space following the withdrawal of Trodelvy in bladder cancer and its late-stage fail in NSCLC.
December 3, 2024
·
2 min read
·
Tristan Manalac
Press Releases
Roivant Announces Topline Results from Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis
December 3, 2024
·
8 min read
Press Releases
Terns Pharmaceuticals Announces Positive Early Data from Phase 1 CARDINAL Trial of TERN-701 for Chronic Myeloid Leukemia
December 3, 2024
·
11 min read
Press Releases
Kinevant Sciences Announces Topline Results from Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis
December 3, 2024
·
4 min read
Press Releases
Keros Therapeutics Announces Global License Agreement with Takeda to Advance Elritercept
December 3, 2024
·
6 min read
Press Releases
Coherus Announces Agreement to Divest UDENYCA® Franchise for up to $558 million to Intas Pharmaceuticals Ltd.
December 3, 2024
·
15 min read
1 of 83,247
Next
